Rapt Therapeutics will “reduce its workforce by 47 people, or approximately 40% of the Company’s existing headcount” in order to conserve cash resources, the company revealed in an SEC filing dated July 19. The South San Francisco–based biotech suffered a setback in February when the FDA placed a hold on two Phase II trials of its candidate zelnecirnon after a case of liver failure. In addition to zelnecirnon, which is being developed for asthma and atopic dermatitis, Rapt has a second clinical-stage candidate, tivumecirnon, in trials for cancer.
https://www.biospace.com/biospace-layoff-tracker